Hematology/oncology clinicians have the opportunity to improve outcomes in patients with AML by expanding their awareness of new evidence-based practices and their ability to implement these practices. The goal of this continuing medical education activity is to increase knowledge and competency among hematology/oncology clinicians regarding best practices in the management of AML, ultimately improving complete remission rate and overall survival in patients with AML.
Hematologist, oncologist, and other health professionals involved in the care of patients with AML.
- Implement current best practices in the use of cytogenetic and molecular markers to guide selection of therapy for patients with AML.
- List characteristics that are considered important in indicating treatment of AML in older adults.
- Develop individualized treatment plans for older adults with AML who may benefit from non-intensive therapy.
- Outline safety and efficacy data for the use of new and emerging targeted treatment approaches for patients with AML.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
Mikkael A. Sekeres, MD, MS (Moderator)
Associate Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland Clinic Taussig Cancer Institute
Department of Hematologic Oncology and Blood Disorders
Elihu Estey, MD
Professor of Medicine
University of Washington Medical Center
Fred Hutchinson Cancer Research Center
Seattle Cancer Center Alliance
Richard Stone, MD
Professor of Medicine
Harvard Medical School
Director, Adult Leukemia Program
Dana-Farber Cancer Institute
The “Conflict of Interest Disclosure Policies” of Albert Einstein College of Medicine of Yeshiva University require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.
Dr. Sekeres discloses that he is a consultant to Amgen and Celgene, and he is on the speakers’ bureau for Celgene.
Dr. Estey has no relevant financial conflicts to disclose.
Dr. Stone discloses that he received funding for clinical research from Novartis and is a consultant to or on a steering committee/DSMB for Agios, Ariad, Celgene, Genzyme, Novartis, and Sunesis.
Disclosure of Unlabeled Use
The Albert Einstein College of Medicine of Yeshiva University (Einstein) also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
©2012, Albert Einstein College of Medicine of Yeshiva University and MCM Education. All rights reserved. This publication is designed to provide the health care professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. None of the contents may be reproduced in any form without prior written permission from Albert Einstein College of Medicine and the publisher. The opinions expressed in this video roundtable are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine, or Boehringer Ingelheim Pharmaceuticals, Inc. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks or without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.
This program is sponsored by Albert Einstein College of Medicine of Yeshiva University.
This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc.
For full program information, please click on “BEGIN” button and follow the next click-through to reach this program site. Once you get to the “CMEcorner.com” site description page, you will review program information, program content, take the test, complete evaluation, and receive credit with a post-test score of at least 60%.
If you have any questions relating to the accreditation of this activity, please contact:
Center for Continuing Medical Education
Bronx, NY 10467
If you have any questions relating to other issues of this activity, please contact myCME.Support@haymarketmedical.com.
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.